ArticleNeurogenetics2025
Computational association in parkinson's disease SNPs with brain structural and functional alterations.
Article in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder which seriously affects human health. Worldwide, there has been a significant increase in the incidence rate of PD reported in many populations. Several epigenetic factors are associated with pathogenesis of the PD. SNCA, LRRK2, NURR1, ATP13A2, GSK3B, Parkin, PINK1, DJ-1, and UCHL1are the major genes involved and play a crucial role in the regulatory mechanisms and progression of PD. In this study, a comprehensive approach was used to identify single nucleotide polymorphisms (SNPs) that have a high deleterious effect on the nine proteins mentioned above. In this approach the SNPs of the genes listed above were subjected to more than 13 different computational tools specifically based on sequence, structural and functional analyses. The Frustrometer, NetSurf 3.0, and xProtCAS servers were used to screen the highly deleterious SNPs. Subsequently, modelling of the mutant proteins, structural analysis, STRING analysis, and binding site analysis were performed and compared with wild type proteins. Finally, the highly deleterious missense variants of the SNPs were subjected to molecular docking analysis with FDA-approved drugs for PD. The results indicate that one of the FDA drug compounds exhibits a high binding affinity across all targets. Subsequently, molecular dynamics simulations were performed on the identified compound. These results provide new insights into the genetic variants linked to PD and contribute to the exploration of future research directions in the field of PD.
Indexed as
Identifiers
40782224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.